10:45 AM EDT, 06/23/2025 (MT Newswires) -- Sana Biotechnology ( SANA ) shares rose 12% in recent trading Monday after the company reported positive six-month results from a first-in-human study evaluating UP421, an allogeneic islet cell therapy for type 1 diabetes.

The treatment showed potential to function without the need for immunosuppression, the company said Monday in a statement.

UP421, which uses Sana's hypoimmune technology to engineer pancreatic islet cells, was found to be safe, well-tolerated and capable of evading immune detection, and the transplanted cells survived and continued producing insulin in the patient, the company said.

Pancreatic islet function and persistence were confirmed by consistent C-peptide, a biomarker of insulin production, which also increased after a mixed meal tolerance test, the company said.

Price: 2.92, Change: +0.32, Percent Change: +12.23